EANS-Stimmrechte: Epigenomics AG / Korrektur der Veröffentlichung gemäß § 26 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung vom 10. Aug. 2012, 14:13 Uhr

Stimmrechtsmitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich.

Mitteilung nach § 21 Abs. 1 WpHG (Aktie)

Correction of Voting Rights Notification dated 10 August 2012: Release of a Voting Rights Notification Pursuant to Sec. 26 para. 1 WpHG (German Securities Trading Act) with the Aim of a Europe-wide Distribution

Issuer:

Epigenomics AG
Kleine Präsidentenstr. 1
10178 Berlin
Germany

Corrected Voting Rights Notification:

On 6 August 2012, Baker Bros. Advisors, LLC, New York, NY, USA notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no. 6 WpHG as follows:

On 12 April 2012, the share of Baker Bros. Advisors, LLC in the voting rights of Epigenomics AG exceeded the 3 per cent threshold as well as the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 6.33 per cent of the voting rights (557,956 voting rights) in Epigenomics AG.

6,33 per cent of the voting rights (557,956 voting rights) are attributed to Baker Bros. Advisors, LLC, pursuant to sec. 22 para. 1 sent. 1 no. 6 WpHG inter alia through Baker Brothers Life Sciences, L.P.

Furthermore, on 6 August 2012, Baker Bros. Advisors, LLC, New York, NY, USA notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no. 6 WpHG as follows:

On 31 July 2012, the share of Baker Bros. Advisors, LLC in the voting rights of Epigenomics AG fell below the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 4.61 per cent of the voting rights (406,186 voting rights) in Epigenomics AG.

4.61 per cent of the voting rights (406,186 voting rights) are attributed to Baker Bros. Advisors, LLC, pursuant to sec. 22 para. 1 no. 6 WpHG inter alia through Baker Brothers Life Sciences, L.P.

Furthermore, on 6 August 2012 and 8 August 2012, Julian Baker, USA, notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no. 1 and no. 6, sent. 2 WpHG and sec. 22 para. 2 WpHG as follows:

On 31 July 2012, the share of Julian Baker in the voting rights of Epigenomics AG fell below the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 4.61 per cent of the voting rights (406,186 voting rights) in Epigenomics AG.

All 4.61 per cent of the voting rights (406,186 voting rights) are attributed to Julian Baker pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG of which 4.49 per cent of the voting rights (396,198 voting rights) are attributed through the following entities controlled by Julian Baker the voting rights of which exceed 3 per cent:

  • Baker Brothers Life Sciences Capital (GP), LLC
  • Baker Brothers Life Sciences Capital, L.P.
  • Baker Brothers Life Sciences, L.P. The 4.61 per cent of the voting rights (406,186 voting rights) are also attributed to Julian Baker pursuant to sec. 22 para. 1 sent. 1 no. 6, sent. 2

WpHG. In addition, all 4.61 per cent of the voting rights are attributed to Julian Baker pursuant to sec. 22 para. 2 WpHG. 4.49 per cent of the voting rights (396,198 voting rights) are attributed from Baker Brothers Life Sciences, L.P.

Furthermore, on 6 August 2012 and 8 August 2012, Felix J. Baker, USA, notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no.1 and no. 6, sent. 2 WpHG and sec. 22 para. 2 WpHG as follows:

On 31 July 2012, the share of Felix J. Baker in the voting rights of Epigenomics AG fell below the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 4.61 per cent of the voting rights (406,186 voting rights) in Epigenomics AG.

All 4.61 per cent of the voting rights (406,186 voting rights) are attributed to Felix J. Baker pursuant to sec. 22 para. 1 sent. 1 no.1 WpHG of which 4.49 per cent of the voting rights (396,198 voting rights) are attributed through the following entities controlled by Felix Baker the voting rights of which exceed 3 per cent:

  • Baker Brothers Life Sciences Capital (GP), LLC
  • Baker Brothers Life Sciences Capital, L.P.
  • Baker Brothers Life Sciences, L.P. The 4.61 per cent of the voting rights (406,186 voting rights) are also

attributed to Felix J. Baker pursuant to sec. 22 para. 1 sent. 1 no. 6, sent. 2 WpHG. In addition, all 4.61 per cent of the voting rights are attributed to Felix J. Baker pursuant to sec. 22 para. 2 WpHG. 4.49 per cent of the voting rights (396,198 voting rights) are attributed from Baker Brothers Life Sciences, L.P.

Furthermore, on 6 August 2012, Baker Brothers Life Sciences Capital (GP), LLC, New York, NY, USA notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no. 1 WpHG and sec. 22 para. 2 WpHG as follows:

On 31 July 2012, the share of Baker Brothers Life Sciences Capital (GP), LLC in the voting rights of Epigenomics AG fell below the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 4.61 per cent of the voting rights (406,186) in Epigenomics AG.

4.49 per cent of the voting rights (396,198 voting rights) are attributed to Baker Brothers Life Sciences Capital (GP), LLC pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG through the following entities controlled by Baker Brothers Life Sciences Capital (GP), LLC the voting rights of which exceed 3 per cent:

  • Baker Brothers Life Sciences Capital, L.P.
  • Baker Brothers Life Sciences, L.P. 0.11 per cent of the voting rights (9,988 voting rights) are attributed to

Baker Brothers Life Sciences Capital (GP), LLC pursuant to sec. 22 para. 2 WpHG.

Furthermore, on 6 August 2012, Baker Brothers Life Sciences Capital, L.P., New York, NY, USA notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no. 1 WpHG and sec. 22 para. 2 WpHG as follows:

On 31 July 2012, the share of Baker Brothers Life Sciences Capital, L.P. in the voting rights of Epigenomics AG fell below the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 4.61 per cent of the voting rights (406,186) in Epigenomics AG.

4.49 per cent of the voting rights (396,198 voting rights) are attributed to Baker Brothers Life Sciences Capital, L.P. pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG through the following entity controlled by Baker Brothers Life Sciences Capital, L.P. the voting rights of which exceed 3 per cent:

- Baker Brothers Life Sciences, L.P.

0.11 per cent of the voting rights (9,988 voting rights) are attributed to Baker Brothers Life Sciences Capital, L.P. pursuant to sec. 22 para. 2 WpHG.

Furthermore, on 6 August 2011, Baker Brothers Life Sciences, L.P., New York, NY, USA notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 2 WpHG as follows:

On 31 July 2012, the share of Baker Brothers Life Sciences, L.P. in the voting rights of Epigenomics AG fell below the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 4.61 per cent of the voting rights (406,186 voting rights) in Epigenomics AG.

0.11 per cent of the voting rights (9,988 voting rights) are attributed to Baker Brothers Life Sciences, L.P. pursuant to sec. 22 para. 2 WpHG.

Furthermore, on 6 August 2012, 14159 Capital (GP), LLC, New York, NY, USA notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no. 1 WpHG and sec. 22 para. 2 WpHG as follows:

On 31 July 2012, the share of 14159 Capital (GP), LLC in the voting rights of Epigenomics AG fell below the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 4.61 per cent of the voting rights (406,186 voting rights) in Epigenomics AG.

0.11 per cent of the voting rights (9,988 voting rights) are attributed to 14159 Capital (GP), LLC pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG.

4.49 per cent of the voting rights (396,198 voting rights) are attributed to 14159 Capital (GP), LLC pursuant to sec. 22 para. 2 WpHG through Baker Brothers Life Sciences, L.P.

Furthermore, on 6 August 2012, 14159 Capital, L.P., New York, NY, USA notified Epigenomics AG of voting rights held in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no. 1 WpHG and sec. 22 para.2 WpHG as follows:

On 31 July 2012, the share of 14159 Capital, L.P. in the voting rights of Epigenomics AG fell below the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 4.61 per cent of the voting rights (406,186 voting rights) in Epigenomics AG.

0.11 per cent of the voting rights (9,988 voting rights) are attributed to 14159 Capital, L.P. pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG.

4.49 per cent of the voting rights (369,198 voting rights) are attributed to 14159 Capital, L.P. pursuant to sec. 22 para. 2 WpHG through Baker Brothers Life Sciences, L.P.

Furthermore, on 6 August 2012 and 8 August 2012, 14159, L.P., New York, NY, USA, notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para.2 WpHG as follows:

On 31 July 2012, the share of 14159, L.P. in the voting rights of Epigenomics AG fell below the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 4.61 per cent of the voting rights (406,186 voting rights) in Epigenomics AG.

4.49 per cent of the voting rights (369,198 voting rights) are attributed to 14159, L.P. pursuant to sec. 22 para. 2 WpHG through Baker Brothers Life Sciences, L.P.

Date of release: 17 August 2012

Epigenomics AG
The Executive Board

Ende der Mitteilung euro adhoc

Emittent: Epigenomics AG Kleine Präsidentenstraße 1 D-10178 Berlin Telefon: +49 30 24345-0 FAX: +49 30 24345-555 Email: ir@epigenomics.com WWW: http://www.epigenomics.com Branche: Biotechnologie ISIN: DE000A1K0516 Indizes: Prime All Share, Technology All Share Börsen: Freiverkehr: Berlin, München, Hamburg, Düsseldorf, Stuttgart, Regulierter Markt/Prime Standard: Frankfurt Sprache: Deutsch

Rückfragen & Kontakt:

Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS | OTB0011